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Primary focal segmental glomerulosclerosis (FSGS) is a
disease with poor prognosis and high unmet therapeutic
need. Here, we evaluated the safety and pharmacokinetics of
single-dose infusions of fresolimumab, a human monoclonal
antibody that inactivates all forms of transforming growth
factor-b (TGF-b), in a phase I open-label, dose-ranging study.
Patients with biopsy-confirmed, treatment-resistant, primary
FSGS with a minimum estimated glomerular filtration rate
(eGFR) of 25ml/min per 1.73m
2, and a urine protein to
creatinine ratio over 1.8mg/mg were eligible. All 16 patients
completed the study in which each received one of four
single-dose levels of fresolimumab (up to 4mg/kg) and
was followed for 112 days. Fresolimumab was well tolerated
with pustular rash the only adverse event in two patients.
One patient was diagnosed with a histologically confirmed
primitive neuroectodermal tumor 2 years after fresolimumab
treatment. Consistent with treatment-resistant FSGS, there
was a slight decline in eGFR (median decline baseline to final
of 5.85ml/min per 1.73m
2). Proteinuria fluctuated during the
study with the median decline from baseline to final in urine
protein to creatinine ratio of 1.2mg/mg with all three Black
patients having a mean decline of 3.6mg/mg. The half-life of
fresolimumab was B14 days, and the mean dose-normalized
Cmax and area under the curve were independent of dose.
Thus, single-dose fresolimumab was well tolerated in
patients with primary resistant FSGS. Additional evaluation in
a larger dose-ranging study is necessary.
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Focal segmental glomerulosclerosis (FSGS) is a clinical entity
that impacts renal function through progressive ﬁbrosis of the
glomerulus. FSGS is not a single disease; rather, it is a
heterogeneous clinicopathological process identiﬁed in renal
biopsies that are generally performed in patients with
proteinuria or nephrotic syndrome. Idiopathic or primary
FSGS has a distinctive histopathological appearance, char-
acterized by hyalinization and sclerosis of a portion of the
glomerular tuft, minimal deposition of immune complexes,
and effacement of visceral epithelial cell (podocyte) foot
processes. Idiopathic FSGS can be distinguished from
secondary causes of FSGS (for example, genetic mutations,
medications, infections, reﬂux nephropathy, or surgical
reduction in renal mass) by more widespread podocyte
effacement together with the presence of nephrotic syndrome.
1
The implication for making the distinctions is that primary
FSGS may respond to corticosteroids or other immunosup-
pression therapy, whereas secondary forms are treated by
addressing the underlying cause. Regardless of the etiology of
FSGS, the majority of cases are characterized by progressive
renal ﬁbrosis and steady deterioration in kidney function.
2–4
In FSGS, the beneﬁcial effects of angiotensin-converting
enzyme inhibitor treatment on proteinuria and preservation
of renal function have led to their widespread use in this
population.
5–12 High-dose and/or prolonged oral corticoster-
oid therapy has been the primary treatment for FSGS and a
treatment response indicates a better long-term outcome in a
small percentage of patients.
13,14 Cyclosporine is the only
agent that has been documented to be efﬁcacious for
reduction of proteinuria in controlled trials in both children
and adults with steroid-resistant FSGS.
15–18 There are also
uncontrolled studies suggesting that tacrolimus, sirolimus,
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19–25 However, in the majority
of primary FSGS patients, treatment with steroids and other
therapeutic interventions result in only transient improve-
ment in proteinuria and does not alter disease course.
26 This
may be especially true in patients with genetic mutations
leading to FSGS.
1,27 Because of the poor prognosis of and the
lack of a proven treatment for patients with steroid-resistant
FSGS, there is a pressing need for new treatments that can
reduce proteinuria and slow down or stop the progression of
renal damage.
Several lines of evidence point toward an important role of
transforming growth factor-b (TGF-b) in disease pathogen-
esis and progression of primary FSGS. TGF-b is well known
to be a modulator of extracellular matrix production and is
associated with interstitial ﬁbrosis in renal disease.
28 More
recently, TGF-b has been recognized as a key regulator of the
glomerular visceral epithelial cell, or podocyte, a pivotal cell
in the pathogenesis of FSGS. Overexpression of TGF-b in
podocytes leads to podocytopenia and glomerulosclerosis.
29
In cultured podocytes, TGF-b inﬂuences cell survival
29–32 and
induces changes in the cytoskeleton and cell adhesion that
are analogous to in vivo foot process effacement.
33 TGF-b
also activates several signaling pathways, including the Smad
cascade, that have demonstrated roles in glomerular
pathogenesis in animal models.
34,35 Both FSGS patients and
experimental animal models demonstrate increased expres-
sion of TGF-b in the kidney and increased urinary excretion
of the growth factor.
36 Biopsies of FSGS patients reveal
increased immunostaining for TGF-b in glomerular en-
dothelial cells.
37 Therefore, these ﬁndings suggest that
modulation of TGF-b activity within the kidney, with
consequent effects on key cell components of the glomerulus
and signaling molecules, may be renoprotective and have a
beneﬁcial effect on the severity or progression of FSGS.
One strategy for altering TGF-b is by antagonism with a
monoclonal antibody. Fresolimumab, a member of the G4
immunoglobulin (IgG4) subclass, is an engineered human
monoclonal antibody that neutralizes all three isoforms of
TGF-b. This IgG subclass does not activate the complement
pathway, a potential favorable feature of the antibody. Data
from diverse animal models demonstrate that neutralization
of TGF-b can inhibit tissue ﬁbrosis.
38 For example,
therapeutic administration of a mouse analog of fresolimu-
mab (1D11) to a murine model of chronic cyclosporine
nephropathy reduced collagen deposition, epithelial cell
apoptosis, and normalized tissue hypoxia.
39 1D11 has also
been shown to preserve glomerular selectivity and prevent
ultrastructural changes to the glomerular ﬁltration barrier
during hypertension.
40 In a model of diabetic nephropathy,
administration of 1D11 combined with enalapril was
antihypertensive, antiproteinuric, reduced glomerulosclero-
sis, and preserved podocyte number.
41 These results provide
evidence that TGF-b antagonism is effective in preventing
and reducing the structural and functional consequences of
chronic renal injury.
The primary objectives of this phase I clinical trial in
patients with treatment-resistant primary FSGS and nephro-
tic-range proteinuria were to determine: (1) the safety and
tolerability of single-dose infusions of fresolimumab; and (2)
the pharmacokinetics of fresolimumab following single-dose
infusions of fresolimumab. The secondary objective was to
obtain preliminary data about the effect of single-dose
infusions of fresolimumab on proteinuria and kidney
function.
RESULTS
Patients
All 16 patients who were enrolled completed the study, 4 at
each dose level. Of the 16 patients, 9 (4 patients in the 1mg/kg
group, 2 patients in the 2mg/kg group, and 3 patients in the
4mg/kg group) had detectable levels of fresolimumab at day
112. They returned for follow-up visits until fresolimumab
was no longer detectable in the blood. The longest duration
of additional follow-up after day 112 was 141 days.
The mean age of the patients was 37±12 years, mean
FSGS duration was 3.0±2.1 years, half were male, 13 were
White, and 3 were Black. Overall, the baseline characteristics
of the patients were similar between dose groups (Table 1 and
Supplementary Table S1 online).
At the time of enrollment, 15 out of 16 (94%) patients
were on a concomitant medication. The most commonly
prescribed drugs were agents acting on the renin-angiotensin
system in 14 cases. A total of 12 subjects were receiving a
lipid-lowering agent, 11 were given a diuretic, and 4 were
receiving aspirin. The use of these agents was comparable in
the four patient cohorts.
Safety results
Fresolimumab was well tolerated at single doses up to the
maximum level of 4mg/kg in patients with FSGS. No patient
withdrew consent or discontinued participation before
completing the study. No profound immunologic or systemic
inﬂammatory reactions were seen in any patient. The DMC
(Data Monitoring Committee) recommended continued
dosing following each dosing cohort.
Infusion-associated reactions, deﬁned as events that
occurred within 24h of infusion and assessed by the
investigator as related to fresolimumab, were noted in only
one patient who had a cough during infusion of the antibody.
The frequencies of reported treatment-emergent adverse
events (TEAEs) were similar across the dose groups. Of the
16 patients, 15 (93.8%) reported a total of 73 TEAEs. The
most frequent TEAEs reported were peripheral edema
(4 patients) and nasopharyngitis (3 patients); all other
TEAEs were reported by p2 patients. All TEAEs except 1
(grade 3 urticaria in a patient with a history of urticaria) were
of grade 1 or 2 intensity (mild or moderate). Overall,
7 patients (43.8%) experienced at least 1 TEAE that was
considered by the investigator to be related to the study drug
(Table 2). Pustular rash, reported by 2 (12.5%) patients,
was the most frequently reported related TEAE. All other
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individual patients. All related TEAEs resolved by the end of
the patient’s participation in the study. No patients
experienced a serious TEAE or died during the study.
Following completion of the study, 1 patient was diagnosed
with a histologically conﬁrmed primitive neuroectodermal
tumor 2 years posttreatment.
No pattern in differences between dose cohorts was
observed for vital signs, physical examination ﬁndings,
gingival examination ﬁndings, electrocardiograph ﬁndings,
or renal function. Changes from baseline in safety laboratory
parameters ﬂuctuated over the course of the study and no
consistent differences between dose cohorts were noted for
laboratory evaluation results.
In three patients (two patients in the 1mg/kg group and
one in the 2mg/kg group), the anti-fresolimumab antibody
assay showed positive results when fresolimumab was no
longer detectable in the blood. No clinical consequences were
noted in the patients with detectable antibody response to
fresolimumab.
Pharmacokinetics
Mean serum concentrations of fresolimumab over time are
presented by dose in Figure 1. The pharmacokinetics of
Table 1|Patient demographics in patients receiving fresolimumab by dose
0.3mg/kg (N=4) 1mg/kg (N=4) 2mg/kg (N=4) 4mg/kg (N=4) Total (N=16)
Age (years), mean±s.d. 33.0±12.4 33.8±14.3 44.3±6.7 38.5±13.4 37.4±11.8
Male gender, n (%) 1 (25.0) 3 (75.0) 1 (25.0) 3 (75.0) 8 (50.0)
Race, n (%)
Black 0 2 (50.0) 1 (25.0) 0 3 (18.8)
White 4 (100.0) 2 (50.0) 3 (75.0) 4 (100.0) 13 (81.3)
Duration since FSGS diagnosis (years), mean±s.d. 3.9±3.4 1.8±1.5 3.2±1.2 3.0±1.6 3.0±2.1
Baseline Up/c ratio (mg/mmol), median 845.0 666.1 376.2 713.5 736.5
Baseline eGFR (ml/min per 1.73m
2), median 36.2 38.8 39.3 62.4 38.6
Abbreviations: eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; Up/c, urine protein:creatinine ratio.
To convert mg/mmol to mg/mg, divide by 113.11.
Table 2|Treatment-related adverse events
System organ class/preferred term
0.3mg/kg
(N=4), n (%)
1mg/kg
(N=4), n (%)
2mg/kg
(N=4), n (%)
4mg/kg
(N=4), n (%)
Total
(N=16), n (%)
Any related adverse event (AE) 1 (25) 3 (75) 1 (25) 2 (50) 7 (43.8)
Gastrointestinal disorders 0 0 1 (25) 1 (25) 2 (12.5)
Gingival bleeding 0 0 1 (25) 0 1 (6.3)
Vomiting 0 0 0 1 (25) 1 (6.3)
Infections and infestations 0 0 0 2 (50) 2 (12.5)
Rash pustular 0 0 0 2 (50) 2 (12.5)
Musculoskeletal and connective tissue disorders 1 (25) 0 0 0 1 (6.3)
Growing pains 1 (25) 0 0 0 1 (6.3)
Renal and urinary disorders 0 1 (25) 0 0 1 (6.3)
Renal impairment 0 1 (25) 0 0 1 (6.3)
Respiratory, thoracic and mediastinal disorders 0 1 (25) 0 0 1 (6.3)
Cough 0 1 (25) 0 0 1 (6.3)
Skin and subcutaneous tissue disorders 0 1 (25) 0 1 (25) 2 (12.5)
Pruritus 0 0 0 1 (25) 1 (6.3)
Vitiligo 0 1 (25) 0 0 1 (6.3)
If a patient had more than one event for a particular system organ class or preferred term, he/she is counted only once for that system organ class of preferred term.
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Figure 1|Mean serum fresolimumab concentration over time.
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linear model. There was no difference in the pharmacokinetic
behavior of fresolimumab in the FSGS cohort compared
with the results observed in two other disease populations
(idiopathic pulmonary ﬁbrosis and advanced malignancy).
42,43
Patient weight was the only signiﬁcant covariate identiﬁed as
being predictive of pharmacokinetic variability. Derived
pharmacokinetic parameters for fresolimumab in FSGS
patients are presented in Table 3. The half-life of fresolimu-
mab in this patient population was B14 days. Values of mean
dose-normalized Cmax and area under the curve values
ranged from 0.27 to 0.37mg/ml/mg and from 48.3 to
88.1ng*h/ml/mg, respectively, and appeared to be indepen-
dent of dose (Table 3).
Efficacy measures
Proteinuria ﬂuctuated during the study period and the
median change from baseline to the ﬁnal study visit in urine
protein:creatinine ratio (PCR) for entire patient cohort was
 133.31mg/mmol ( 1.2mg/mg; Table 4). A graphic illus-
tration of the time course of the response for each cohort is
available as Figure 2. A clinically signiﬁcant improvement in
proteinuria was observed in the three Black patients (two
from the fresolimumab 1mg/kg cohort and one from the
2mg/kg cohort). These three individuals demonstrated a
mean decrease of 65% in urine PCR levels at the ﬁnal study
visit compared with baseline (Table 5).
The overall trend was for a slight decline in estimated
glomerular ﬁltration rate (eGFR): the median change from
baseline at the ﬁnal study visit was  5.85ml/min per 1.73m
2
(annualized:  19.0ml/min per 1.73m
2) with no dose-related
differences. For the other efﬁcacy measures assessed, results
tended to ﬂuctuate over the course of the study with no
treatment-related changes noted (Table 4).
DISCUSSION
This report describes a phase 1, open-label study conducted
in patients with treatment-resistant primary FSGS that was
designed to assess the safety, tolerability, and pharmacoki-
netics of single-dose infusions of fresolimumab. The study
agent was safely administered to four patients in each of four
dose cohorts: 0.3, 1, 2 and 4mg/kg body weight. All 16
patients who received a single dose of the antibody completed
the study.
This trial represents the ﬁrst description of the use of an
anti-TGF-b antibody that has appeared in a peer-reviewed
publication. It is important to emphasize that this phase I
study involved patients with fairly advanced disease based on
their resistance to previous treatments and the low eGFR
criterion for eligibility. Thus, like patients with oncological
diseases, the expectation of therapeutic beneﬁt from a single
dose of the anti-TGF-b antibody was low. The primary
objective was to evaluate the safety and pharmacokinetics of
fresolimumab. The assessment of clinical response was a
secondary objective and the ﬁndings in this regard should be
considered preliminary and proof-of-concept only.
There were no complications related to the infusion or
that occurred within the 24-h observation period after
administration of the antibody. Reporting of long-term
adverse events and related adverse events was similar across
the dose cohorts. All adverse events except one were of
mild or moderate intensity. No patients experienced a serious
TEAE, discontinued study participation because of an adverse
event, or died during the study. The overall safety proﬁle
in these 16 patients can be added to the over 50 patients
who have received single or multiple doses of fresolimumab
in clinical trials of patients with idiopathic pulmonary
ﬁbrosis (n¼25) and cancer (n¼29) (refs 42, 43). Overall,
no consistent differences between dose cohorts were noted
Table 3|Pharmacokinetic parameters after a single dose of fresolimumab
Dose (mg/kg) Cmax (lg/ml) Cmax/dose (lg/ml/mg) AUC (ng*h/ml) AUC/dose (ng*h/ml/mg) T1/2a (day) T1/2b (day) CL (ml/h) Vss (ml)
0.3 5.70±1.85 0.31±0.11 1162±492 63.9±27.2 2.73±1.15 10.9±5.1 19.7±13.0 4.48±2.14
1 19.3±3.59 0.27±0.05 3484±405 48.3±9.0 2.73±1.93 17.0±8.7 21.1±3.9 6.65±2.06
2 47.5±5.54 0.32±0.03 13,016±2814 88.1±16.0 2.61±1.73 17.7±3.7 11.6±2.2 5.17±1.47
4 114±16.3 0.37±0.02 26,175±7964 82.9±19.7 2.92±1.79 34.6±47.7
a 12.6±2.8 3.56±0.60
Abbreviations: AUC, area under the curve; CL, clearance; Cmax, maximum concentration; T1/2a, distribution half-life; T1/2b, elimination half-life; Vss, volume of distribution
at steady state.
aValue appears to be elevated because of one patient. Median half-life was 12.5 days.
Values are presented as mean±s.d.
Table 4|Median change from baseline to final study visit in estimated glomerular filtration rate (eGFR), urine protein/
creatinine ratio, urine albumin/creatinine ratio, serum creatinine, and serum albumin
0.3mg/kg (N=4) 1mg/kg (N=4) 2mg/kg (N=4) 4mg/kg (N=4) Total (N=16)
eGFR (ml/min per 1.73m
2)  5.65  6.25  3.05  9.25  5.85
Urine protein/creatinine ratio (mg/mmol)  140.1  331.2 77.4  126.5  133.3
Urine albumin/creatinine ratio (mg/mmol)  93.8  101.9 105.2  122.3  57.8
Serum creatinine (mmol/l) 7.0 23.5 16.0 27.0 17.5
Serum albumin (g/l) 0.0 1.5 2.0 2.0 1.5
To convert mg/mmol to mg/mg, divide by 113.11.
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examination including gingival examination ﬁndings, or
electrocardiograph ﬁndings. There was one patient who was
diagnosed with a primitive neuroectodermal tumor 2 years
after receiving the single 1mg/kg dose of fresolimumab.
He was in complete remission from his FSGS, his kidney
function was unaltered from the baseline, and fresolimumab
was undetectable in his serum for 41 year before the
diagnosis of the malignancy. In a repeat-dose oncology study
with fresolimumab, squamous cell skin cancer was reported
in two patients with advanced malignant melanoma who
received multiple doses every 2 weeks (up to 15mg/kg) of
fresolimumab.
43 Although it is unlikely that fresolimumab
was directly linked to the primitive neuroectodermal tumor,
monitoring for both expected and unanticipated side effects,
including infection, autoimmunity, and malignancy, should
be incorporated into future clinical studies with this agent.
The pharmacokinetics of fresolimumab observed in this
study were similar to that observed in studies of fresolimu-
mab in patients with idiopathic pulmonary ﬁbrosis and
advanced malignancy. Cmax and area under the curve were
dose proportional over the range of doses tested, indicating
that fresolimumab exhibits linear kinetics and that drug
clearance was not saturable. The elimination half-life was
B14 days in patients with FSGS. This pharmacokinetic
proﬁle is consistent with the pharmacokinetics of mono-
clonal antibodies that neutralize soluble antigens (that is,
cytokines).
44 The dosing interval to be used in future studies
will be dependant on both the pharmacokinetic proﬁle and
the pharmacological activity of fresolimumab. A dosing
interval of at least 2 weeks is expected to result in minimal
accumulation of the antibody.
Exploratory clinical outcomes were evaluated; however,
assessment of efﬁcacy in treatment-resistant primary FSGS
was not a primary objective of this phase I study. Moreover,
the results are limited because of the small sample size, lack of
a placebo-controlled comparison group, and a single-dose
treatment design. Despite these limitations, the PCR declined
in three patients. These patients, who were the only Blacks
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Figure 2|Urine protein/creatinine ratio by cohort over time.
Table 5|Urine protein to creatinine ratio for patients with a
reduction from baseline
Patient 1003 1004 2004
Dose 1mg/kg 1mg/kg 2mg/kg
Race Black Black Black
Preinfusion (mg/mmol) 559.28 772.81 402.52
End of study (mg/mmol) 228.12 61.75 231.97
To convert mg/mmol to mg/mg, divide by 113.11.
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original article H Trachtman et al.: Fresolimumab in resistant primary FSGSenrolled in the study, demonstrated a clinically meaningful
decrease in urine PCR levels. In one case, the patient achieved
nearly a complete remission (PCR o0.3), in the second,
there was nearly a partial remission (50% reduction in PCR
to a level o2), and the third had a substantial 42% lowering
in PCR. No other routine clinical or laboratory feature
discriminated between those who had a reduction in
proteinuria and those who manifested no short-term
response to the experimental intervention. The ﬁnding is
encouraging because reduction of proteinuria is critical to a
patient’s clinical course. Complete remission of primary
FSGS is clearly linked to a favorable outcome, even if patients
have a subsequent relapse.
26 Nonetheless, intermediate
reductions in urine protein excretion are also associated
with improved patient outcomes. This beneﬁcial impact of
treatments that reduce but do not normalize proteinuria has
been documented in children and adults with FSGS and
other glomerulopathies.
45–48 However, caution is advisable in
interpreting the clinical ﬁndings in this small patient cohort.
The overall trend observed in GFR values in this study
cohort was slightly downward, although sporadic, variable,
and not dose related. This ﬁnding is consistent with that
expected over a 4-month time period in patients with
resistant FSGS.
47–48 There was no evidence that administra-
tion of the anti-TGF-b antibody accelerated the downward
course of the disease. For the other clinical outcomes
assessed, results tended to ﬂuctuate over the course of the
study with no treatment-related changes noted.
In summary, the results of this phase I clinical trial
indicate that fresolimumab, administered as a single-dose
infusion up to 4mg/kg, is safe and well tolerated in patients
with treatment-resistant primary FSGS. This provides
justiﬁcation for moving forward with larger randomized
clinical trials to assess efﬁcacy of this agent in patients with
primary FSGS who are resistant to corticosteroids and other
immunosuppressive agents.
PATIENTS AND METHODS
Patient selection
Patients with treatment-resistant primary FSGS aged X18
years at nine centers in the United States, Germany, Italy, and
the United Kingdom received a single fresolimumab infusion
between May 2007 and August 2009. Patients with FSGS who
in the investigator’s opinion represented primary disease with
eGFR X25ml/min per 1.73m
2 and persistent proteinuria
(urine PCR 4200mg/mmol (1.8mg/mg)) and who had
demonstrated resistance to steroid or other immunosuppres-
sive agent were eligible for enrollment in the study, indicating
that the patients were at high risk of progression to end-stage
kidney disease. The patients did not have to manifest clinical
evidence of nephrotic syndrome, namely edema, to qualify
for the study. Biopsy slides were reviewed centrally to
conﬁrm the diagnosis and they were classiﬁed according to
the Columbia scheme.
49 Secondary FSGS was excluded based
on this internationally accepted FSGS classiﬁcation. Patients
were excluded from the study if they had clinical evidence of
secondary FSGS including diabetes type 2, segmental
hypoplasia, oligomeganephronia, unilateral renal agenesis,
renal dysplasia, cortical necrosis, surgical renal ablation,
chronic allograft nephropathy glomerulonephritis, atheroem-
boli or other vaso-occlusive processes, cyanotic congenital
heart disease, sickle cell anemia, hypertension, infection,
morbid obesity, reﬂux nephropathy, lymphomas, or other
malignancies; sarcoidosis, radiation therapy, membranous
nephropathy or IgA nephropathy viral infections (including
hepatitis B, human immunodeﬁciency virus and parvovirus
B19) or drug induced (for example, heroin, interferon A,
lithium, pamidronate), current or history of any form of
skin cancer; a history of other cancers or a known
precancerous state; pre-existing oral-pharyngeal disease; a
bleeding diathesis; any clinically signiﬁcant medical condition
including congestive heart failure, hepatic, or gastrointestinal
disease; or were pregnant or lactating women.
The protocol and informed consent were reviewed and
approved by an independent ethics committee at each
participating site. All patients provided written, informed
consent before the initiation of any study-related activities.
This research was carried out in accordance with Good
Clinical Practice guidelines and applicable regulations.
Study design
This was a phase 1, open-label, single-dose, dose-ranging
study. Eligible patients were enrolled and allocated to one of
four dosing cohorts. The original protocol speciﬁed that
patients were to receive 1, 2, 4, or 8mg/kg. However, based
on preliminary results suggesting a response in patients who
received the lowest dose (1mg/kg), the dose range was
changed to 0.3, 1, 2, and 4mg/kg of fresolimumab to identify
a minimal noneffective dose. As 0.3mg/kg was lower than the
starting dose of 1mg/kg, the 0.3 and 4mg/kg groups were
run concurrently. Patients were randomized to either 0.3 or
4mg/kg to mitigate any potential for bias.
In each cohort, patients received a single dose of
fresolimumab infused over 30min. Actual body weight was
used to calculate the dose for patients with body mass index
o30kg/m
2. For patients with body mass index X30kg/m
2,
ideal body weight calculation was used. Patients were
followed periodically for 112 days (days 4, 7, 14, 21, 28, 56,
84, and 112) for safety evaluations, pharmacokinetics, and
clinical outcome and biomarker assessments. Any patient
whose blood level of fresolimumab was still detectable at
study completion was to return every 4 weeks until no further
fresolimumab was detected.
An independent DMC reviewed study safety data after each
cohort in order to make a recommendation on continued dosing.
This clinical study (GC1008FSGS00505) was funded by
Genzyme Corporation. The protocol was drafted by the
sponsor, Genzyme, in conjunction with the team of
investigators. The sponsor performed the data and analysis
and the investigators reviewed and veriﬁed the results. The
ﬁrst draft of the manuscript was written by the sponsor
together with the lead academic author. It was edited by all of
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and the accuracy of the analysis. The decision to submit the
manuscript represents a consensus of all representatives from
the sponsor and the academic authors. The authors acknowl-
edge Rasha Aguzzi, Sara Engstrand, Antony Jack, Joan
Mannick, and Melissa Plone of Genzyme Corporation for
assistance in study planning, implementation, and analysis
and interpretation of the data.
Biochemical measurements
Fresolimumab concentrations were determined using a
validated solid-phase enzyme-linked immunosorbent assay
with colorimetric detection.
To detect antifresolimumab antibodies, serum samples
were initially screened in a bridging enzyme-linked immuno-
sorbent assay in a 1:30 ﬁnal dilution. Samples with a result
above the limit of detection were then titred in a conﬁr-
matory binding inhibition assay. Analyses for antifresolimu-
mab antibodies were only conducted on serum samples
without detectable fresolimumab, as it interferes with the
immunogenicity assay.
Statistical analyses
Sample size. No formal sample size calculations were
done for this study. The sample size was selected to allow for
adequate assessment of pharmacokinetics at each dose level,
and also to allow for an initial assessment of safety in this
population and dose range.
Safety assessments. Adverse events were summarized
by dose group. Changes in vital signs, weight, electrocardio-
graph, development of antibodies to fresolimumab, and shifts
in laboratory assessments and physical examinations includ-
ing gingival examinations, were assessed.
Pharmacokinetics. Pharmacokinetic data from the present
trial were pooled with data from additional phase 1 trials
conducted in patients with idiopathic pulmonary ﬁbrosis
and advanced malignancy
46,47 and analyzed using nonlinear
mixed effect modeling methods. A population pharmacoki-
netic model that adequately characterizes the data was
selected based on model development and was parameterized
accordingly. Covariate models were tested to evaluate the
effect of patient characteristics (for example, weight, age,
gender, and disease state) on the pharmacokinetics of
fresolimumab. Values for derived pharmacokinetic para-
meters, including Cmax, area under the curve, distribution
half-life (T1/2a), elimination half-life (T1/2b), clearance (CL),
and volume of distribution at steady state (Vss), were
calculated for patients with FSGS using the ﬁnal pharmaco-
kinetic model and summarized by dose group using
descriptive statistics.
Efficacy measures. Changes from baseline in urine PCR,
eGFR, albumin/creatinine ratio, serum creatine, and albumin
were summarized for each dose.
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